Sweden
Medical Products Agency (Läkemedelsverket) (MPA (LV))
Sweden regulates pharmaceutical products through the Medical Products Agency — Läkemedelsverket (MPA / LV), an EU member authority operating under the Medicinal Products Act (Läkemedelslagen 2015:315) and fully aligned with EU pharmaceutical legislation. MPA is a voting member of EMA's scientific committees (CHMP, PRAC, CAT, COMP, PDCO, HMPC) and CMDh, a founding PIC/S member, and a frequent Rapporteur and Reference Member State, particularly for biologics, oncology and Nordic-relevant generics. EMA Centralised Procedure authorisations are directly valid in Sweden via Commission Implementing Decision; DCP, MRP and national procedures are handled by MPA. The dossier follows EU eCTD; English is the working language for assessment, with Swedish required for SmPC (Produktresumé), PIL (Bipacksedel) and labelling. Sweden is part of the EU/EEA Falsified Medicines framework via e-VIS / NMVS Sweden and applies EU GMP/GDP via PIC/S. Public-sector access splits between outpatient prescription medicines reimbursed under the pharmaceutical benefits scheme (Läkemedelsförmånerna) administered by Tandvårds- och läkemedelsförmånsverket (TLV) — Sweden's HTA agency — and hospital medicines funded by the 21 regions (Regioner), coordinated through the National Process for Ordered Introduction of New Pharmaceuticals (NT-rådet) with TLV health-economic assessments. Sweden does not operate statutory international reference pricing for outpatient medicines; instead TLV applies a value-based pricing framework with cost-effectiveness analysis against severity-graded thresholds.
About the authority
Läkemedelsverket (MPA) is Sweden's competent authority for human and veterinary medicines, medical devices, cosmetics, tattoo inks and narcotics control. Headquartered in Uppsala (with offices in Stockholm), it reports to the Ministry of Social Affairs (Socialdepartementet) and is led by a Director-General appointed by the Government. MPA covers marketing authorisation, GMP/GDP inspection, pharmacovigilance, clinical trial authorisation under the EU CTR via CTIS, narcotics scheduling and a national pharmacopoeia function. MPA is a frequent EMA Rapporteur (top-tier in Europe by volume per capita) and a Reference Member State of choice for Nordic-focused DCP/MRP procedures, with strong oncology, biologics and rare-disease assessment expertise.
International affiliations
Reliance & recognition
Sweden is fully integrated into the EU regulatory network as a Member State. EMA centralised authorisations apply directly via Commission Implementing Decision (no national mirror required). DCP and MRP enable cross-recognition with EU/EEA partners. MPA collaborates closely with Nordic regulators (Norway DMP, Denmark DKMA, Finland Fimea, Iceland IMA) under the Nordic Pharmaceutical Forum, and supports joint Nordic assessments and information sharing. Outside the EU/EEA framework, Sweden does not operate a standalone reliance pathway for non-EU SRA decisions.
Compare Sweden side-by-side
Benchmark timelines, fees and pathway requirements against another market.
Other Europe markets
Same structure. Same source-citation standard.